Sh.I. Musin1, A.V. Sultanbaev1,2, K.V. Menshikov1,2, M.M. Zamilov1, N.I. Sultanbaeva1, I.A. Menshikova2, D.O. Lipatov2
1Republican Clinical Oncology Dispensary, Ufa
2Bashkir State Medical University, Ufa
Musin Shamil I. — Cand. of Sci. (Med.), Head of Surgical Department №6 of the Republican Clinical Oncology Dispensary
73/1 Oktyabrya Ave., Ufa, 450054, Russian Federation, e-mail: email@example.com, ORCID ID: 0000-0003-1185-977X
Abstract. One of the most problematic nosologies among squamous cell carcinoma of the head and neck is cancer of the larynx. Until now, the therapy for squamous cell carcinoma of the head and neck has remained unchanged and is based on combinations with platinum-containing therapy. One of the promising areas for the treatment of common tumors is immunotherapy. The results of the KEYNOTE-040 study indicate the possibility of prolonging disease control after disease progression on first-line platinum-containing chemotherapy. This publication analyzes a case of treatment with the checkpoint inhibitor — Pembrolizumab. After platinum-containing chemotherapy, immunotherapy in the 2nd line made it possible to achieve tumor control in the form of a partial response within 17 months of therapy. As a result of treatment with pembrolizumab, an adverse event was not registered in a patient.
Key words: unresectable cancer of the larynx, immunotherapy, disease control, partial response.